1998 clinical practice guidelines for the management of diabetes in Canada. Canadian Diabetes Association.
S. J. Meltzer, Donna Lillie, Hertzel C. Gerstein(McMaster University), Jean‐François Yale(McGill University Health Centre), L. A. Leiter, David C.W. Lau(University of Calgary), Sora Ludwig, Bernard Zinman(Mount Sinai Hospital), Denis Daneman(Hospital for Sick Children)
PubMed
January 1, 1998
Cited by 215
Related Papers
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
|New England Journal of Medicine|2015|11.9k
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|New England Journal of Medicine|2019|6k
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
|New England Journal of Medicine|2016|3.6k
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
|New England Journal of Medicine|2015|2.6k
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
|New England Journal of Medicine|2015|2.3k